Since the discovery of iPS cells in 2006, the field of stem cell research has developed greatly. However in order for iPS cells to be put to practical use in the society and to save lives, there are still many obstacles that need to be overcome. While being encouraged by the expectations of many people, through trial and error for the past decade, we have continued to make discoveries and develop new techniques.
On the other hand, the use of drugs such as anticancer, antibacterial and analgesic agents may be restricted due to adverse reactions on the heart (cardiotoxicity). The cost and time spent evaluating adverse reactions including cardiotoxicity are becoming a problem.
It is highly anticipated that the implementation of iPS cells will make it possible to develop novel drugs and therapies that have never been seen before. Recently, many other cell-based products that use not only iPS cells but also mesenchymal stem cells and lymphocytes are proactively being developed. These products are beginning to reach patients who respond poorly to conventional treatments.
We are convinced that the era in which “cells” change the world significantly is coming.
By utilizing all kinds of biotechnology-centered engineering, we achieve breakthroughs and novel infrastructure technology in the field of regenerative medicine and drug discovery to the world.
“The dream of every cell is to become two cells.” François Jacob
The iPS cells we are cultivating increase 100-fold per week. According to calculations, if we kept growing cells for three and half months without any restrictions, we could produce organ cells equivalent to the size of about 100 globes.
However, in reality, companies around the world that develop cell products are facing problems such as medium cost, culture space, and an inability to structure multiple cells in the same way as human organs.
Tackling common problems around the world, we have been working on the development and social implementation of the infrastructure technology necessary for cell culture, such as the production of iPS cell-derived cardiomyocytes using protein-free mediums and the development of manufacturing processes occasionally in collaboration with manufacturers of equipment, culture substrates, and chemical products.
We utilize our accumulated experience, and adopt all kinds of biotechnology-centered engineering to pursue the optimal culture media, optimal culture substrates, and optimal manufacturing processes for various types of cells. We believe that the key to realizing a society where the benefits of cell technology can be spread to people, not just a few, is to prepare a comfortable environment for the cells and steadily eliminate each factor that inhibit cell growth.
In order to develop a city, infrastructure technology for building roads and bridges is essential. The world of biotechnology, including regenerative medicine and cellular drug discovery, is no exception.
We will proceed with our business step by step so that the new breakthroughs and infrastructure technologies we have put into the world will further contribute to the development of the regenerative medicine industry and drug discovery technology, transcending corporate and national borders.
- Kentaro Ishida
- Chief Researcher
- Mayu Morishima
- Outside Director Beyond Next Ventures
- Yoshihiro Kidachi
- Outside Auditor BOIDSCraft Corporation